Larger subcutaneous injection volumes (above 0.5mL) can cause more local discomfort, swelling, and slower absorption
Bush M, Scott R, Watanalumlerd P, et al
Data in weight loss Most of the existing empirical data on weight loss with GLP-1 agonists come from studies of individuals who are overweight or obese, with or without type 2 diabetes, rather than from studies using these agents to counteract iatrogenic weight gain
Gastrointestinal adverse events, including nausea, vomiting, constipation, and diarrhea, were the most frequently reported events across treatment groups and were observed most commonly in the liraglutide group
What to watch for FDA enforcement actions against specific compounding pharmacies
Diagnosis of mitochondrial disorders by concomitant next-generation sequencing of the exome and mitochondrial genome